Cingulate Inc. Warrants (CINGW)
$0.01
$0.00
(-31.58%)
As on 27-Aug-2026 15:57EDT
Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
$-57.69 Mln
EBITDA
$-77.14 Mln
Net Profit
$-80.85 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cingulate Inc. Warrants (CINGW)
| -85.7 | -53.3 | -58.9 | -84.4 | -58.7 | -- | -- |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Cingulate Inc. Warrants (CINGW)
| 6.2 | 70.9 | -85.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Cingulate Inc. Warrants (CINGW)
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead... product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas. Read more
-
CEO & Chairman of the Board
Dr. Shane J. Schaffer Pharm.D., PharmD
-
CEO & Chairman of the Board
Dr. Shane J. Schaffer Pharm.D.
-
Headquarters
Kansas City, KS
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cingulate Inc. Warrants (CINGW)
What is the current share price of Cingulate Inc Warrants (CINGW) Today?
The share price of Cingulate Inc Warrants (CINGW) is $0.01 (NASDAQ) as of 27-Aug-2026 15:57 EDT. Cingulate Inc Warrants (CINGW) has given a return of -58.73% in the last 3 years.
What is the current PB & PE ratio of Cingulate Inc Warrants (CINGW)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.01 |
0.12 |
2024 |
-0.01 |
0.02 |
2023 |
0.00 |
-0.01 |
2022 |
-0.02 |
0.08 |
2021 |
-0.04 |
0.04 |
What is the 52 Week High and Low of Cingulate Inc Warrants (CINGW)?
The 52-week high and low of Cingulate Inc Warrants (CINGW) are Rs 0.12 and Rs 0.00 as of 29-Aug-2026.
What is the market cap of Cingulate Inc Warrants (CINGW)?
Cingulate Inc Warrants (CINGW) has a market capitalisation of -- as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cingulate Inc Warrants (CINGW)?
Before investing in Cingulate Inc Warrants (CINGW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.